CXBS Corix Bioscience Inc (CE)

Item 4.01 Changes in Registrant’s Certifying Accountant

The Board of Directors for Corix Bioscience, Inc., a Wyoming corporation (the “Company”) and Malone Bailey, LLP, the Company’s independent auditor (“MB”) have collectively decided that the Company will retain a new independent auditor moving forward. The new independent auditor, which has yet to be named, will perform the audit associated with the Company’s forthcoming 2017 Annual Report on Form 10-K (“Annual Report”). As a result of this change, there is a possibility that the Company will be unable to timely file its Annual Report. MB’s reports on the Company’s financial statements for the year ended December 31, 2016 and December 31, 2015 contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles   other than to state that there is substantial doubt as to the ability of the Company to continue as a going concern.

During the Company’s most recent fiscal year and the subsequent interim period preceding MB’s dismissal, there were: (i) no “disagreements” (within the meaning of Item 304(a) of Regulation S-K) with MB on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of MB, would have caused it to make reference to the subject matter of the disagreements in its reports on the financial statements of the Company; and (ii) no “reportable events” (as such term is defined in Item 304(a)(1)(v) of Regulation S-K). The Company has provided MB with a copy of this Form 8-K prior to its filing with the United States Securities and Exchange Commission (“SEC”) and requested MB furnish to the Company a letter addressed to the SEC stating that it agrees with the statements made above. A copy of MB’s letter is attached as Exhibit 16.1 to this Form 8-K.